We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$3.89B
1-Year Est. Return
201.1%
This Fund
S&P 500
This Quarter
Est. Return
-3.63%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.14B
AUM Growth
-$232M
(-9.8%)
Cap. Flow
-$62.6M
Cap. Flow
% of AUM
-2.93%
Top 10 Holdings %
Top 10 Hldgs %
61.97%
Holding
57
New
7
Increased
13
Reduced
4
Closed
8
Top Buys
| 1 |
Erasca
ERAS
|
+$35M |
| 2 |
Disc Medicine
IRON
|
+$33M |
| 3 |
AnaptysBio
ANAB
|
+$29.5M |
| 4 |
Savara
SVRA
|
+$18.5M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$18.1M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$124M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$52M |
| 3 |
JBIO
Jade Biosciences
JBIO
|
+$35.6M |
| 4 |
Structure Therapeutics
GPCR
|
+$27M |
| 5 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$22.9M |
Sector Composition
| 1 | Healthcare | 99.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NewAmsterdam Pharma
NAMS
$3.7B
| $235M | 10.99% |
12,226,943
| – | – |
|
2
Mirum Pharmaceuticals
MIRM
$7.18B
| $222M | 10.39% |
6,495,392
| – | – |
|
3
Krystal Biotech
KRYS
$10.2B
| $182M | 8.49% |
988,460
| – | – |
|
|
HLVX
4
DELISTED
HilleVax
HLVX
| $154M | 7.18% |
10,617,062
+835,590
| +9% | +$11.5M |
|
5
Phathom Pharmaceuticals
PHAT
$878M
| $104M | 4.87% |
10,109,279
| – | – |
|
6
Rhythm Pharmaceuticals
RYTM
$7.28B
| $97.4M | 4.55% |
2,371,304
+181,125
| +8% | +$7.23M |
|
7
BridgeBio Pharma
BBIO
$16B
| $92M | 4.3% |
3,632,604
+217,000
| +6% | +$5.93M |
|
8
Arcutis Biotherapeutics
ARQT
$3.46B
| $81.7M | 3.82% |
8,785,284
| – | – |
|
|
9
Disc Medicine
IRON
$2.81B
| $79.1M | 3.7% |
1,754,834
+969,834
| +124% | +$33M |
|
10
Vaxcyte
PCVX
$7.99B
| $78.5M | 3.67% |
1,039,405
-100,000
| -9% | -$6.81M |
|
11
Edgewise Therapeutics
EWTX
$4.14B
| $67.2M | 3.14% |
3,731,067
+427,500
| +13% | +$7.46M |
|
|
12
AnaptysBio
ANAB
$1.6B
| $54.3M | 2.54% |
2,165,591
+1,265,891
| +141% | +$29.5M |
|
|
VRNA
13
DELISTED
Verona Pharma
VRNA
| $47.9M | 2.24% |
3,314,349
+300,000
| +10% | +$4.38M |
|
|
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
| $43.4M | 2.03% |
3,687,867
| – | – |
|
15
Tarsus Pharmaceuticals
TARS
$2.57B
| $43.1M | 2.02% |
1,587,527
-200,000
| -11% | -$6.72M |
|
16
Revolution Medicines
RVMD
$37.9B
| $38.7M | 1.81% |
997,455
| – | – |
|
|
17
Erasca
ERAS
$6.01B
| $38.3M | 1.79% |
+16,216,216
| New | +$35M |
|
18
Agios Pharmaceuticals
AGIO
$2.31B
| $37.6M | 1.76% |
871,974
+348,808
| +67% | +$12.6M |
|
|
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
| $35.7M | 1.67% |
875,667
| – | – |
|
20
Rocket Pharmaceuticals
RCKT
$380M
| $33.6M | 1.57% |
1,561,230
| – | – |
|
|
21
Savara
SVRA
$1.15B
| $32.9M | 1.54% |
8,157,385
+4,157,385
| +104% | +$18.5M |
|
22
Oric Pharmaceuticals
ORIC
$1.09B
| $29.3M | 1.37% |
4,142,855
| – | – |
|
23
CG Oncology
CGON
$6.15B
| $24.3M | 1.14% |
770,000
| – | – |
|
24
PepGen
PEPG
$153M
| $24M | 1.12% |
1,502,788
| – | – |
|
|
MRUS
25
DELISTED
Merus
MRUS
| $22.1M | 1.03% |
373,100
-373,379
| -50% | -$18.1M |
|
Similar funds
GAMH
MSI
CCM
TFM
SCM
MIM
AA
DACG